Hayden is an associate editor for The American Journal of Managed Care® (AJMC®). She joined the AJMC team in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
The Pharmacist’s Role in Value-Based Oncology Models: David Awad, PharmD, BCOP
Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, BCOP, of Robert Wood Johnson University Hospital.
Cost and Infrastructure Slow Cardiac PET Adoption: Merrill Stewart, MD
Merrill H. Stewart, MD, Ochsner Health, outlines the financial, logistical, and reimbursement barriers slowing the adoption of cardiac stress testing, but growing recognition of its long-term value could drive wider use.
Cost and Coverage Issues Drive GLP-1 Discontinuation: Hamlet Gasoyan, PhD
Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP-1) receptor agonists, reducing their effectiveness for weight loss, explains Hamlet Gasoyan, PhD, Cleveland Clinic.
Pharmacists Essential to Expanding CAR T, Bispecific Access: David Awad, PharmD, BCOP
David Awad, PharmD, BCOP, says pharmacists play a growing role in managing access, safety, and toxicity for these therapies, ensuring treatments are appropriate and sustainable in real-world oncology practice.